- Home
- TZUP vs CVKD Comparison
TZUP vs CVKD Comparison
Compare TZUP & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TZUP
- CVKD
- Stock Information
- Founded
- TZUP 2020
- CVKD 2022
- Country
- TZUP United States
- CVKD United States
- Employees
- TZUP N/A
- CVKD N/A
- Industry
- TZUP
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- TZUP
- CVKD Health Care
- Exchange
- TZUP NYSE
- CVKD Nasdaq
- Market Cap
- TZUP 38.8M
- CVKD 31.5M
- IPO Year
- TZUP N/A
- CVKD 2023
- Fundamental
- Price
- TZUP $5.02
- CVKD $16.88
- Analyst Decision
- TZUP
- CVKD Strong Buy
- Analyst Count
- TZUP 0
- CVKD 1
- Target Price
- TZUP N/A
- CVKD $32.00
- AVG Volume (30 Days)
- TZUP 123.9K
- CVKD 20.4K
- Earning Date
- TZUP 01-01-0001
- CVKD 05-08-2025
- Dividend Yield
- TZUP N/A
- CVKD N/A
- EPS Growth
- TZUP N/A
- CVKD N/A
- EPS
- TZUP N/A
- CVKD N/A
- Revenue
- TZUP $741.00
- CVKD N/A
- Revenue This Year
- TZUP N/A
- CVKD N/A
- Revenue Next Year
- TZUP N/A
- CVKD N/A
- P/E Ratio
- TZUP N/A
- CVKD N/A
- Revenue Growth
- TZUP N/A
- CVKD N/A
- 52 Week Low
- TZUP $2.02
- CVKD $5.70
- 52 Week High
- TZUP $7.89
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- TZUP N/A
- CVKD 50.50
- Support Level
- TZUP N/A
- CVKD $15.85
- Resistance Level
- TZUP N/A
- CVKD $17.33
- Average True Range (ATR)
- TZUP 0.00
- CVKD 1.44
- MACD
- TZUP 0.00
- CVKD 0.18
- Stochastic Oscillator
- TZUP 0.00
- CVKD 72.23
About TZUP THUMZUP MEDIA CORP
Thumzup Media Corp operates in the social media branding and marketing industry. The company operates in a single business segment which is social media marketing. The Thumzup App works on both iPhone and Android mobile operating systems and connects brands and people who use and love these brands. The easy-to-use dashboard allows advertisers to programmatically customize their campaigns. Cash payments are made to App users/creators through Venmo and PayPal.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.